2019 Health for Humanity Report
Healthcare for All Lead Image
Healthcare for All Lead Image

Mlolongo Blue Box Clinic, Kenya.

Better Health for All
Better Health for All Enhancing Access to Healthcare
SASB
  • HC-BP-240a.2
    List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)

Improving Access & Affordability

We pursue a wide variety of approaches appropriate to the specific reimbursement systems and legal guidelines of different countries. Using tools such as equity-based tiered pricing and partnerships with public health organizations, we strive to help achieve broad and timely access to our medicines in a way that is affordable locally. Three ongoing access initiatives reflected in our Health for Humanity 2020 Goals Progress Scorecard for those in resource-constrained settings include:

  • Expanding access to HIV/AIDS treatment, developing the first HIV vaccine, and improving HIV diagnostics;
  • Ensuring affordable and sustainable access to multidrug-resistant tuberculosis treatments; and
  • Promoting treatments to address neglected tropical diseases.

Johnson & Johnson is an original signatory of the Business for Social Responsibility (BSR) Guiding Principles on Access to Healthcare that underscore the importance of reducing the global burden of disease through collaboration, R&D, expanding availability of healthcare services, developing health systems resources, and respecting human rights.

In the last decade, Johnson & Johnson has ranked among the top three companies worldwide working to expand access to medicines, according to the Access to Medicine Index. The Index, which is compiled by independent experts at the Access to Medicine Foundation, evaluates 20 of the world’s largest research-based pharmaceutical companies on their performance in making medicines, vaccines and diagnostics more accessible to people in need in low- and middle-income countries. The most recent Index, covering 2018, highlights Johnson & Johnson’s unique global public health business approach, commitment to R&D for diseases of the developing world, and leadership in health system strengthening, as well as efforts to overcome antimicrobial resistance through our work to eradicate tuberculosis.

Highlight
Highlight
6 Johnson & Johnson products are included in the WHO List of Prequalified Medicinal Products:
  • Darunavir (ethanolate), Tablet, Film-coated 75mg
  • Darunavir (ethanolate), Tablet, Film-coated 150mg
  • Darunavir (ethanolate), Tablet, Film-coated 600mg
  • Etravirine, Tablet, Film-coated 100mg
  • Etravirine, Tablet 25mg
  • Mebendazole, Tablets, Chewable 500mg
Challenging entrepreneurs to enhance access to healthcare in Africa
In 2019, our second Africa Innovation Challenge, with its goal of stimulating entrepreneurship and innovation in Africa, attracted almost 900 applicants from 39 countries who submitted inspiring proposals to improve health and wellbeing in their communities and beyond.

The six winners, selected by Johnson & Johnson healthcare leaders from our three business segments and corporate functions, each received a grant of $50,000 and mentoring support to address unmet needs across critical healthcare areas.

The winning proposals included a digital platform that enables delivery of lifesaving blood to hospitals in less than 45 minutes (LifeBank, Nigeria); a mobile phone app for remote hearing tests for children in rural Africa (Dreet, Botswana); an organic, affordable soap that repels mosquitoes to help prevent the spread of malaria (Uganics, Uganda), and a solar-powered, foldable crib that helps jaundiced babies receive important phototherapy to help them regain health (Crib A’Glow, Nigeria).

Access and affordability for patients in the U.S.: In the United States, we provide resources to patients, caregivers and healthcare providers through the Janssen CarePath program, which helps patients gain and maintain access to the Janssen medicines they are prescribed.

Janssen CarePath programs help patients navigate complex payer processes, connect with savings programs, and stay on their prescribed medications. These strategies have the potential to lead to better quality of care and outcomes. Programs under the Janssen CarePath brand also aid adherence to prescribed therapies and support patients, providers, and caregivers in accessing and affording prescribed Janssen medications.

Transparent performance on access and pricing
Headlines from the 2019 Janssen U.S. Transparency Report:
  • In 2019, the average net price of our medicines declined (1.2)%.
  • This decline reflects the $24.5 billion in discounts, rebates, and fees we provided to intermediaries in the system—more than half the list price of our medicines.
  • We maintained our significant investment in discovering and developing new medicines for patients—spending 91% more on global R&D than on global marketing and sales. In the last five years, we’ve spent $39.4 billion on R&D, resulting in seven new medicines and 38 new indications.
  • We helped 1.3 million patients with access, affordability and treatment support through Janssen CarePath.
  • We worked with stakeholders to advance practical policy solutions to reduce costs for patients, while supporting continued progress in the fight against disease.
For more information, see the 2019 Janssen U.S. Transparency Report.

Our initiatives in 2019 include:

  • Mobile enrollment on Janssen CarePath: We introduced a new capability on Janssen CarePath, enabling U.S. SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) patients to initiate enrollment in the Janssen CarePath Savings Program for Infectious Diseases by texting from their phone. Eligible patients can send a text to enroll in the program on their smartphone and receive an electronic savings program card that can be saved to a digital wallet on their mobile device.
  • Enhancing access in Kenya: In partnership with Kenya’s National Hospital Insurance Fund (NHIF), we are enhancing access to ZYTIGA (abiraterone acetate), a drug used to treat an advanced form of prostate cancer. The new partnership will allow more patients to be diagnosed and treated earlier through a patient assistance program for NHIF-member patients.
  • Enhancing access in China: Johnson & Johnson Medical Devices in Shanghai partnered with TINAVI, the market leader in orthopaedic robotics in China. This strategic collaboration will allow DePuy Synthes, our orthopaedics business, to bring TINAVI’s robotic solutions for spine and trauma surgery to the China orthopaedics implant market. To date, TINAVI is the only arm-based robotic technology with multiple indications approved for use in spine and trauma in China.
This is an important milestone in the field of digital surgery. We will work to create an open innovation ecosystem, promote digital and technological medical innovation, provide insights for the Chinese medical industry through local collaboration, optimize patient experience, and help upgrade the health industry, so that more people can access more convenient and better medical services to achieve the great vision of 'Healthy China 2030'.
Will Song Chairman, Johnson & Johnson China, and President, Johnson & Johnson Medical China (Shanghai) Ltd.

  • Mobile education facility for healthcare professionals (HCPs): For many HCPs who cannot travel for training, the Johnson & Johnson Institute Mobile Lab, an 18-wheeler truck equipped with the latest in surgical simulation training, travels to them. The Mobile Lab teaches orthopaedic trauma, joint reconstruction, spine, sports and craniomaxillofacial procedures in a setting that simulates the Operating Room, offering participants hands-on experience with relevant instrumentation and techniques. Over the course of 2019, the Mobile Lab visited 30 cities across the United States and trained 466 HCPs who otherwise might not have had access to a similar educational opportunity.

Intellectual Property

We believe that flexible intellectual property (IP) management is a key element to effective and sustainable access to medicines, especially in low-income and low- to middle-income countries. IP systems encourage innovation and allow us to invest in new technologies, fund R&D, and bring transformational medicines to the market. We work with international funders, local governments and non-governmental organizations to develop approaches that benefit patients in need while continuing to uphold the value of IP in all parts of the world. For more information, see our Position on Intellectual Property.

Advancing public policy on patents to benefit patients: In 2019, the Subcommittee on Intellectual Property of the U.S. Senate Judiciary Committee heard testimony from healthcare experts on proposed reforms to the subject matter eligibility requirements defined in Section 101 of the Patent Act. As current case law relating to patent eligible subject matter is both confusing and complex, the reform efforts seek to restore clarity and predictability to these requirements. Johnson & Johnson, the world’s largest healthcare company and a transformational medical innovator, believes that clarity and predictability of the patent system are essential for ongoing drug development. Robert DeBerardine, Chief Intellectual Property Counsel, Johnson & Johnson, provided testimony to the Subcommittee at their hearings in June. Mr. DeBerardine testified: “Without the investment of larger pharmaceutical and biotechnology companies, basic research could not be transformed into safe and effective treatments that benefit patients. We strongly support the approach taken in the proposal to fix our current patent eligibility problem.”

Back To Enhancing Access to Healthcare Up Next Universal Health Coverage
You are leaving jnj.com and entering a third-party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties.
Continue